NCT00520910View on ClinicalTrials.gov

Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
AgingSkin Abnormalities
Interventions
DRUG

Polypodium leucotomos

Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.

Trial Locations (1)

33136

University of Miami Skin Research Group Office, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT00520910 - Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers | Biotech Hunter | Biotech Hunter